Tumors with alterations in the CDK12 gene were more responsive to immunotherapy, suggesting a precision medicine approach.
Researchers identify a lncRNA that provides insight into a key driver of prostate cancer — and a potential target for future therapy.
A new model developed by Michigan Medicine researchers could change treatment guidelines for nearly two-thirds of men with localized prostate cancer.
Michigan Medicine experts discuss whether active surveillance — close monitoring without immediate treatment — could reduce overtreatment for some thyroid, prostate and breast cancer patients.
A new review finds that a family history of prostate cancer should not automatically exclude low-risk patients from an active surveillance approach.
A novel strategy to target a genetic anomaly that occurs in half of all prostate cancers may provide a path for developing new therapies against it.